SEC Form 10-Q filed by Kymera Therapeutics Inc.
Unavailable
Unavailable
Date | Price Target | Rating | Analyst |
---|---|---|---|
9/9/2024 | $60.00 | Outperform | Leerink Partners |
8/26/2024 | $65.00 | Peer Perform → Outperform | Wolfe Research |
4/22/2024 | $53.00 | Outperform | Oppenheimer |
2/15/2024 | Peer Perform | Wolfe Research | |
1/4/2024 | Neutral → Overweight | JP Morgan | |
1/3/2024 | $45.00 → $30.00 | Buy → Neutral | BofA Securities |
12/19/2023 | $26.00 | Overweight → Equal Weight | Wells Fargo |
6/30/2023 | $50.00 | Buy | Truist |
SC 13D/A - Kymera Therapeutics, Inc. (0001815442) (Subject)
SC 13D - Kymera Therapeutics, Inc. (0001815442) (Subject)
SC 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)
Sanofi plans to expand KT-474/SAR444656 (IRAK4) Phase 2 clinical trials in HS and AD to accelerate overall development timelines following interim analysis of safety and efficacy data STAT6 degrader program on track to initiate Phase 1 in second half of 2024 with data in first half of 2025; TYK2 degrader program on track to initiate and complete Phase 1 in 2025 Data from KT-253 (MDM2) and KT-333 (STAT3) oncology degrader programs presented at ASCO and EHA, with major responses in liquid and solid tumors; Phase 1a dose escalation studies expected to complete enrollment in second half of 2024 Well-capitalized with $702 million in cash as of June 30, 2024, and runway into the first half of 2
Watertown, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), will report second quarter 2024 financial results on August 7, 2024, and will host a conference call at 8:30 a.m. ET. To access the August 7 conference call via phone, please dial +1 (833) 630-2127 (US) or +1 (412) 317-1846 (International) and ask to join the Kymera Therapeutics call. A live webcast of the Company's conference call will be available under "News and Events" in the Investors section of the Company's website at www.kymeratx.com. A replay of the we
KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of 2025 KT-621 (STAT6) expected to start Phase 1 in the second half of 2024 and KT-294 (TYK2) expected to start Phase 1 in the first half of 2025, both with Phase 1 data in 2025 KT-253 (MDM2) and KT-333 (STAT3) Phase 1 dose escalation studies ongoing with clinical data updates at ASCO and EHA, respectively Well-capitalized with $745 million in cash as of March 31, 2024, and runway into the first half of 2027 Company to hold call and webcast today at 8:30 a.m. ET WATERTOWN, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmac
These ten mid-cap stocks were the best performers in the last week. Are they in your portfolio? QuantumScape Corporation (NYSE:QS) stock jumped 64.34% after the company announced it entered into an agreement with Volkswagen's battery company PowerCo to industrialize solid-state batteries. Lantheus Holdings, Inc. (NASDAQ:LNTH) shares rocketed 55.93% following a CMS proposal to improve payment for Specialized Diagnostic Radiopharmaceuticals. Sunrun Inc. (NASDAQ:RUN) shares increased 37.59%. as shares of companies within the broader industrial sector gained following recent CPI data. Kymera Therapeutics, Inc. (NASDAQ:KYMR) shares rose 37.38% after the company announced its intentio
Oppenheimer analyst Jeff Jones maintains Kymera Therapeutics (NASDAQ:KYMR) with a Outperform and maintains $52 price target.
B. Riley Securities analyst Kalpit Patel maintains Kymera Therapeutics (NASDAQ:KYMR) with a Neutral and raises the price target from $31 to $36.
KT-621 has the potential to provide dupilumab-like activity with an oral small molecule profile for TH2 driven allergic and atopic disease KT-621 demonstrated strong degradation of STAT6 in human sensory neurons resulting in inhibition of IL-13-induced itch- and pain-related gene transcripts with the potential to alleviate these symptoms in atopic dermatitis patients KT-621 expected to start Phase 1 in the second half of 2024, with Phase 1 data in the first half of 2025 WATERTOWN, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradatio
WATERTOWN, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats and presentations at the following upcoming investor events: Wells Fargo 2024 Healthcare Conference in Boston, MA on September 4 at 3:00 p.m. ET;Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY on September 5 at 3:20 p.m. ET;H.C. Wainwright 26th Annual Global Investment Conference in New York, NY on September 9 at 8:00 a.m. ET; and2024 Cantor Fitzgerald Global Healthcar
WATERTOWN, Mass., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the closing of its upsized underwritten public offering of $225 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. Kymera sold and issued 2,830,533 shares of its common stock, which includes 828,220 shares sold and issued upon the full exercise by the underwriters of their option to purchase additional shares of common stock and, in lieu of common stock
144 - Kymera Therapeutics, Inc. (0001815442) (Subject)
144 - Kymera Therapeutics, Inc. (0001815442) (Subject)
144 - Kymera Therapeutics, Inc. (0001815442) (Subject)
Leerink Partners resumed coverage of Kymera Therapeutics with a rating of Outperform and set a new price target of $60.00
Wolfe Research upgraded Kymera Therapeutics from Peer Perform to Outperform and set a new price target of $65.00
Oppenheimer initiated coverage of Kymera Therapeutics with a rating of Outperform and set a new price target of $53.00
4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
Company's focus on advancing first-in-class oral degraders with biologics-like activity to address areas of significant patient need and market potential STAT6 oral degrader KT-621, with dupilumab-like activity, expected to enter Phase 1 clinical trial in the second half of 2024 TYK2 oral degrader KT-294, with a TYK2 loss-of-function profile and expected biologics-like activity, planned to enter Phase 1 clinical trial in the first half of 2025 IRAK4 oral degrader KT-474 (SAR444656) expected to complete enrollment in both Phase 2 HS and AD studies in fourth quarter of 2024, with topline data expected in the first half of 2025 Company to hold virtual Immunology R&D Day webcast today at
WATERTOWN, Mass., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today shared webcast information for the virtual Immunology R&D Day that the Company will host on January 4, 2024, from 10:00 a.m. to 12:00 p.m. ET. The R&D Day will focus on the Company's emerging pipeline of high-value immunology programs, including new target disclosures, supporting preclinical data and timing to clinical study initiation. To join the webcast, please visit this link, or the "Events and Presentations" page of the Investors section on the Company'
WATERTOWN, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced the appointment of Jeremy Chadwick, Ph.D., as Chief Operating Officer. Dr. Chadwick joins Kymera with extensive experience overseeing global development operations, regulatory and program management at a range of biopharmaceutical companies. As a member of the Company's senior management team, Dr. Chadwick will develop and execute near-term and long-range strategies to maximize the impact of Kymera's expanding pipeline. "At Kymera, we ha
4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)